Aradigm is a benefits platform for cell and gene therapies (CGT) designed to provide sustainable access to life-saving medicines. Our novel financial and delivery model addresses the challenges facing every stakeholder—payers, providers, manufacturers, and, most importantly, patients. By creating a large-scale risk pool to cover and pay for all CGT drugs and care, with unspent funds returned, we can deliver cost predictability for employers and health plans. Our end-to-end experience includes a national network of "centers of excellence” and concierge patient support, giving providers volume and rate certainty and patients appropriate, high-quality treatment and outcomes.
Hayward, California, United StatesFounded 199131+ employeesARDM
$75.5M raisedIPO· last: post ipo debt (May 2016)· 3 rounds
Backed by(4 investors)
